Perspective Therapeutics, Inc. · AMEX:CATX
Perspective Therapeutics — Isoray — Investor Presentation (December 2019)
32 slides from Perspective Therapeutics's investor presentation, Dec 10, 2019
Slide 1: The Leader in Brachytherapy – Investor Presentation
isoray The Leader in Brachytherapy December 2019 Investor — Presentation NYSE American: ISR isoray
Slide 2: Safe Harbor Statement
Safe Harbor Statement ‘Statements inthis presentation about|soray'sfuture expectations, including: theanticipated continued growin revenues in fiscal year2020, the advantagesofour products including Blu Buildandthe GammaTile™ Therapy delivery system, whether interest in anduze of our Cesium Blu" pro
Slide 3: Isoray at a Glance
Isoray at a Glance + Consistent Revenue Growth and Improving Gross Profit Trends + TTM Revenue Growth of 28.6%" + TTM Gross Profit Growth of 77.8%" + 53.5% Gross Margin in most recent quarter + Large Opportunity to Gain Share in Core Prostate Market + Brain LDR Brachytherapy is Emerging as an Option
Slide 4: Isoray sole producer of Cesium-131 brachytherapy seeds; Market Data
Isoray, Ine, through its subsidiary Isoray Medical, Inc. isthe sole producer of Cesium-131 brachytherapy seeds, which are expanding bractytheropy treatment options throughout the body. Market Data Ticker (NYSE American) Price (12/09/2019) 52 Week Range Market Cap ‘Average Daily Trading (90 Day) Comm
Slide 5: Revenue Growth
Revenue Growth Market Share & Customer Growth 48% 23% = Revenue Growth Revenue Growth F1Q20 over F1Q19 FY2019 over FY2018 26% Net New Physician Growth 12-months ending 9/30/19 compared to previous 12-months Nationwide Growth In All Sales Territories isoray
Slide 6: Focused on Growth
Focused on Growth Experienced Management Team Loria. Woods Chief Executive Oficer More than 30 years of experience inhealthcareand i well-known andrespected in the brachytherapy community Previously served as VP andCOO of loray from 2006 to 2010, Streamlined manufacturing operations reduced suppl co
Slide 7: A Proven Treatment
A Proven Treatment Brachytherapy Radiotherapy in which sealed sources of radioactive material are implanted in and/or around the affected tissue as close to the cancer as possible Benefits: + Highly targeted treatment dose + Limits dose to surrounding critical structures + Shortened side effects + P
Slide 8: Market Opportunity
Market Opportunity Prostate Growing body of literature supporting outcome benefits of brachytherapy Full solutions for localized disease Increased opportunities for targeted delivery systems Brain + Cesium-131 isemerging as analternativeto other isotopes + Partnership with GT Medical Technologies +
Slide 9: Changing Market Environments
Changing Market Environments Expanding the Brachytherapy Market Proposed changes to the reimbursement that reward cost-effectiveness of procedures * Brachytherapy is included in proposals that bundle payment for radiation treatments. As the lowest cost-option, this could dramatically shift the treat
Slide 10: The Isoray Advantage
The lsoray Advantage The Power of Cesium-131 With a higher energy and a shorter half-life than competitors, Cesium-131 is proven to bea highly effective treatment for patients in the fight against cancer red faster than external + Powerful, continuous, therapeutic energy 9.7 Day Half Life ‘Theamount
Slide 11: An Industry Leader
An Industry Leader Prostate Cancer ‘American Cancer Society estimates 174,650 cases of Prostate Cancer in 2019 + Estimated 122,225 prostate cancers are eligible for brachytherapy as treatment annually + 4/- $585 Million market opportunity if treated with Cesium-131 Clinical data supports Cesium-131
Slide 12: Cesium Blu: High Risk Prostate Patients
Cesium Blu High Risk Prostate Patients High Risk Disease is an immediate opportunity to expand procedures 10,000-15,000 men annually diagnosed as High- Risk + Segment growing due to lessened screening recommendations + Brachytherapy + External Radiation offers better outcomes to men with High Risk P
Slide 13: 10+ Years: The Data is In
10+ Years The Data is In. Isoray's long standing commitment to Cesium-131 in prostate cancer treatment has resulted in the clearing of a significant hurdle to widespread adoption of the isotope. Y Long-term outcomes Y Peer-reviewed literature 2 Prose Long-term biochemical outcomes using cesium-131 i
Slide 14: Product Portfolio
Product Portfolio A Modern Toolset for All Brachytherapy Techniques Blu Build Full Market Release in 2020
Slide 15: Resident & Physician Training
Resident & Physician Training Impact of Training Programs January 1, 2018 - September 30, 2019 + Training the next generation of Cesium-131 ‘San Franciseo)\€A, brachytherapists Training cost of $73k for 11 training programs + Revenue of $565k realized to date él . my Co L_| Longview, TK 3p Bay, WI B
Slide 16: Real-time Planning: Blu Build Delivery System
Real-time Planning Blu Build Delivery System Provides Isoray access to 25% More of the Prostate Market and a Higher ASP Proprietary Delivery Devi rst new tool for prostate brachytherapy in > 10 years * Disposable, single use, next-generation device allows for greater patient throughput, no steriliza
Slide 17: Leading the Industry: Initiatives for Growth in Prostate
Leading the Industry Initiatives for Growth i in Prostate Providing Market + Innovative training program for physicians and residents + lnvesting in clinical data and research + Raising awareness of brachytherapy ‘Digital and Social Media awareness programe + Find aDoctor on Our Website + Supporting
Slide 18: A Growing Opportunity: Brain Cancer
A Growing Opportunity Brain Cancer $218 Million Market Potent’ for Brain Tumors + Provides new treatment option for patients without other options + Brain tumorsimpact~188,820 patients annually + Recurrenceoccurs within 18 months fornearlyall patients treated for braintumors Brachytherapy created hi
Slide 19: Cesium-131 Powers GammaTile Therapy
Cesium-131 Powers Gammavile™ Therapy Collaborative Partnership with GT Medical Technologies + Isoray has exclusive 10 year manufacturing and isotope supply agreement + 510(K) completed, ICD-10-PCS reimbursement code received for recurrent brain tumors + GT Medical Technologies recently applied to FD
Slide 20: Radiation Location and Intensity
Radiation Location and Intensity External Beam Vs. GammaTile™ Therapy Distribution and Intensity —_Distribution and Intensity After Surgery of GammaTile™ Therapy of External Radiation isoray
Slide 21: Pioneering Options: Surgical Opportunities
Pioneering Options Surgical Opportunities Combined $208 Million Market Potential + Cancers with large unmet medical needs increasingly leveraging benefits of Cesium-131 + Cesium-131 placed at the site of tumor recurrence + Immediate radiation delivery, no need for surgical healing + Recent submissio
Slide 22: Pioneering Options: Head & Neck
Pioneering Options Head & Neck Expanding Experience in Head & Neck Cancers + Isoray pioneers first head & neck brachytherapy reimbursement code to be implemented in 2020 for inpatient procedures, expanding patient and physician options + Commercial team supports customers who are interested in offer
Slide 23: Emerging Trends: Immunotherapy
Emerging Trends Immunotherapy + Isoray is committed to the constant study of Cesium-131 as the preferred isotope for emerging treatment options like immunotherapy + We're working with leading US medical institutions to study patient success and bring new innovations to market that build on our exper
Slide 24: Pioneering Options: For Women with GYN Cancers
Pioneering Options For Women with GYN Cancers ‘Success in recurrent gynecological cancer treatment + Initial clinical publications + Additional institutions progressing through adoption process + Alternative is removing all pelvic organs + Implantation into cancers of the cervix and uterus are simil
Slide 25: On-Going Clinical Data
On-Going Clinical Data Growing Clinical Support of Cesium-131 Key on-going data collection + Keyhole Craniotomy Brain Resection plus Cesium-131 at Ochsner Medical Center, New Orleans + Head & Neck treatment in process at Thomas Jefferson and University of Cincinnati + advanced Vaginal, Cervical and
Slide 26: Cesium-131 Targeting > $1B Opportunity
Cesium-131 Targeting > $1B Opportunity Potential Market with Cesium-131 In Millions Lung Cancer Prostate Cancer $57 $585 Head & Neck Tumors $132 Recurrent VN Tumors me Brain Tumors $218 Page 2s isoray
Slide 27: Cesium-131 Targeting >$1B Opportunity
Cesium-131 Targeting >$1B Opportunity Disease State Prostate Cancer Brain Cancer Primary CNS Cancer New Metastases RecurrentCancer Gynecological Cancers Uterus Ovary Cervix Vagina & Other Genital Vulva Head & Neck Tumors Mouth Pharynx Tongue Other oral cavity Lung Cancers Total Opportunity 2019 Esti
Slide 28: Strong Revenue and Gross Margin Trends
Strong Revenue and Gross Margin Trends Consistent Revenue Growth ~ 2 Year CAGR of 28% $2,150 70% $2,500 60% $2,250 50% 3 g 3 3 8 52,000 40% 8 é i 2 s1750 30% H g é $1,250 10% $750 10% 2Q17 3Q1T AQT -—«1QIB_-«- AQIS -3QIB_-AQIS--1QID_«-2QII_«-3Q19.4QID-—-1020 mmm Revenue —=Gross Margin isoray
Slide 29: Income Statement Highlights
Income Statement Highlights 1920 (9/30/19) TTM (9/30/19) (Unaudited) (Unaudited) Sales, Net $2,315 $8,067 CostofSales 1079 4308, GrossProfit 1236 3,759 Research and Development 233 1,287 Salesand Marketing, 815 2,885 Generaland Administrative 1097 4296 Gain on Equipment Disposal - (24) Gain on Chang
Slide 30: Balance Sheet Highlights
Balance Sheet Highlights September 30, 2019 (Unaudited) $00 Cash and Cash Equivalents Total Current Assets Total Current Liabilities Long Term Debt* Shareholders’ Equity Total Liabilities and Shareholders’ Equity Working Capital Current Ratio $4,575 6,806 1,666 6,955 $10,124 $5,140 4,09x June 30, 20
Slide 31: Key Takeaways
lsoray 2019 Key Takeaways Consistent Revenue Growth and Improving Gross Profit Trends + 10 consecutive quarters of double-digit revenue growth with 48% growth in most recent quarter + Following establishment of updated commercial strategyin 2018 + Growing market share (-8-9% current market share) +
Slide 32: For Further Information
For Further Information: Mark Levin Investor Relations (01) 255-1910 mark@globalirgroup.com